12M 2024: Novonesis delivers strong full-year results and expects continued growth in 2025
26/2 08:04
Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin of 36.1% in 2024. For 2025, Novonesis presents an outlook of 5-8% organic sales growth with an adjusted EBITDA margin of 37-38%. COPENHAGEN, Denmark – February 26, 2025. In the 2024 financial year, Novonesis delivers 8% organic sales growth with an adjusted EBITDA margin at […]...